Tonic modulation of anxiety-like behavior by corticotropin-releasing factor (CRF) type 1 receptor (CRF1) within the medial prefrontal cortex (mPFC) in male mice: Role of protein kinase A (PKA)

Hormones and Behavior

Volumn 66, Issue 2, 2014, Pages 247-256

  Miguel, Tarciso Tadeu ^a   Gomes, Karina Santos ^a   Nunes de Souza, Ricardo Luiz ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Anxiety; Corticotrophin releasing factor (CRF); CRF1 receptor; Elevated plus maze; Medial prefrontal cortex (mPFC); Mice; PKA

Indexed keywords

CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CP 376395; CYCLIC AMP DEPENDENT PROTEIN KINASE; N (1 ETHYLPROPYL) 3,6 DIMETHYL 2 (2,4,6 TRIMETHYLPHENOXY) 4 PYRIDINAMINE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; UNCLASSIFIED DRUG; (3,6-DIMETHYL-2-(2,4,6-TRIMETHYLPHENOXY)PYRIDIN-4-YL)(1-ETHYLPROPYL)AMINE; AMINOPYRIDINE DERIVATIVE; ANXIOLYTIC AGENT; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; ISOQUINOLINE DERIVATIVE; N-(2-(4-BROMOCINNAMYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELEVATED PLUS MAZE TEST; ENZYME ACTIVATION; ENZYME ACTIVITY; HISTOLOGY; LIMBIC CORTEX; MALE; MICROPHOTOGRAPHY; MOUSE; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; TRANQUILIZING ACTIVITY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; MICROINJECTION; PHYSIOLOGY; PSYCHOLOGY;

AMINOPYRIDINES; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ISOQUINOLINES; MALE; MICE; MICROINJECTIONS; PREFRONTAL CORTEX; PROTEIN KINASE INHIBITORS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SULFONAMIDES;

EID: 84902248928     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2014.05.003     Document Type: Article

References (52)

1. Adamec R.E., Blundell J., Burton P. Phosphorylated cyclic AMP response element binding protein expression induced in the periaqueductal gray by predator stress: its relationship to the stress experience, behavior and limbic neural plasticity. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27(8):1243-1267.
2. Adamec R.E., Berton O., Razeck W.A. Viral vector induction of CREB expression in the periaqueductal gray induces a predator stress-like pattern of changes in pCREB expression, neuroplasticity and anxiety in rodents. Neural Plast. 2009, 2009. (Article ID 904568, 15 pp.).
3. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., Britton K.T. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology 1991, 103:227-232.
4. Berridge C.W., Dunn A.J. CRF and restraint-stress decrease exploratory behavior in hypophysectomized mice. Pharmacol. Biochem. Behav. 1989, 34:517-519.
5. Bijlsma E.Y., van Leeuwen M.L., Westphal K.G., Olivier B., Groenink L. Local repeated corticotropin-releasing factor infusion exacerbates anxiety- and fear-related behavior: differential involvement of the basolateral amygdala and medial prefrontal cortex. J. Neurosci. 2011, 173:82-92.
6. Blacktop J.M., Seubert C., Baker D.A., Ferda N., Lee G., Graf E.N., Mantsch J.R. Augmented cocaine seeking in response to stress or CRF delivered into the ventral tegmental area following long-access self-administration is mediated by CRF receptor type 1 but not CRF receptor type 2. J. Neurosci. 2011, 31(31):11396-11403.
7. Borelli K.G., Brandão M.L. Effects of ovine CRF injections into the dorsomedial, dorsolateral and lateral columns of the periaqueductal gray: a functional role for the dorsomedial column. Horm. Behav. 2008, 53(1):40-50.
8. Carobrez A.P., Bertóglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20years on. Neurosci. Biobehav. Rev. 2005, 29:1193-1205.
9. Carrasco G.A., Van Der Kar L.D. Neuroendocrine pharmacology of stress. Eur. J. Pharmacol. 2003, 463:235-272.
10. Carvalho-Netto E.F., Litvin Y., Nunes-de-Souza R.L., Blanchard D.C., Blanchard R.J. Effects of intra-PAG infusion of ovine CRF on defensive behaviors in Swiss-Webster mice. Behav. Brain Res. 2007, 176:222-229.
11. Chalmers D.T., Lovenberg T.W., De Souza E.B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J. Neurosci. 1995, 15(10):6340-6350.
12. Chan A.K., von der Weid P.Y. 5-HT decreases contractile and electrical activities in lymphatic vessels of the guinea-pig mesentery: role of 5-HT7-receptors. Br. J. Pharmacol. 2003, 139(2):243-254.
13. Chang C.P., Pearse R.V., O'Connell S., Rosenfeld M.G. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 1993, 11:1187-1195.
14. Chen M.F., Chiu T.H., Lee E.H. Noradrenergic mediation of the memory-enhancing effect of corticotropin-releasing factor in the locus coeruleus of rats. Psychoneuroendocrinology 1992, 17(2-3):113-124.
15. Chen R., Lewis K.A., Perrin M.H., Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:8967-8971.
16. Cohen J. Eta-squared and partial eta-squared in fixed factor ANOVA designs. Educ. Psychol. Meas. 1973, 33:107-112.
17. Contarino A., Dellu F., Koob G.F., Smith G.W., Lee K.F., Vale W., Gold L.H. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. 1999, 835(1):1-9.
18. Eckart K., Jahn O., Radulovic J., Tezval H., van Werven L., Spiess J. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(20):11142-11147.
19. Hauger R.L., Risbrough V., Brauns O., Dautzenberg F.M. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol. Disord. Drug Targets 2006, 5(4):453-479.
20. Hillhouse E.W., Grammatopoulos D.K. The molecular mechanisms underlying the regulation of the biological activity of corticotrophin releasing hormone receptors: implications for physiology and pathophysiology. Endocr. Rev. 2006, 27(3):260-286.
21. Jaferi A., Bhatnagar S.C. Corticotropin-releasing hormone receptors in the medial prefrontal cortex regulate hypothalamic-pituitary-adrenal activity and anxiety-related behavior regardless of prior stress experience. Brain Res. 2007, 1186:212-223.
22. Kabitzke P.A., Silva L., Wiedenmayer C. Norepinephrine mediates contextual fear learning and hippocampal pCREB in juvenile rats exposed to predator odor. Neurobiol. Learn. Mem. 2011, 96(2):166-172.
23. Kageyama K., Hanada K., Moriyama T., Imaizumi T., Satoh K., Suda T. Differential regulation of CREB and ERK phosphorylation through corticotropin-releasing factor receptors type 1 and 2 in AtT-20 and A7r5 cells. Mol. Cell. Endocrinol. 2007, 263(1-2):90-102.
24. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
25. Lister R. Ethologically-based animal models of anxiety disorders. Pharmacol. Ther. 1990, 46:321-340.
26. Litvin Y., Pentkowski N.S., Blanchard D.C., Blanchard R.J. CRF type 1 receptors in the dorsal periaqueductal gray modulate anxiety-induced defensive behaviors. Horm. Behav. 2007, 52(2):244-251.
27. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:836-840.
28. Martins A.P., Marras R.A., Guimarães F.S. Anxiogenic effect of corticotropin-releasing hormone in the dorsal periaqueductal gray. Neuroreport 1997, 8:3601-3604.
29. Miguel T.T., Nunes-de-Souza R.L. Anxiogenic and antinociceptive effects induced by corticotropin-releasing factor (CRF) injections into the periaqueductal gray are modulated by CRF1 receptor in mice. Horm. Behav. 2011, 60(3):292-300.
30. Ohata H., Shibasaki T. Microinjection of different doses of corticotropin-releasing factor into the medial prefrontal cortex produces effects opposing anxiety-related behavior in rats. J. Nippon Med. Sch. 2011, 78(5):286-292.
31. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, California, USA. G. Paxinos, K.B.J. Franklin (Eds.).
32. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
33. Pentkowski N.S., Tovote P., Zavala A.R., Litvin Y., Blanchard D.C., Spiess J., Blanchard R.J. Cortagine infused into the medial prefrontal cortex attenuates predator-induced defensive behaviors and Fos protein production in selective nuclei of the amygdala in male CD1 mice. Horm. Behav. 2013, 64(3):519-526.
34. Perrin M., Donaldson C., Chen R., Blount A., Berggren T., Bilezikjian L., Sawchenko P., Vale W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:2969-2973.
35. Reul J.M., Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2002, 2(1):23-33.
36. Rodgers J.R., Johnson N.J. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 1995, 52(2):297-303.
37. Sahuque L.L., Kullberg E.F., Mcgeehan A.J., Kinder J.R., Hicks M.P., Blanton M.G., Janak P.H., Olive M.F. Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes. Psychopharmacology (Berl.) 2006, 186(1):122-132.
38. Schwabe K., Klein S., Koch M. Behavioural effects of neonatal lesions of the medial prefrontal cortex and subchronic pubertal treatment with phencyclidine of adult rats. Behav. Brain Res. 2006, 168(1):150-160.
39. Shah A.A., Treit D. Infusions of midazolam into the medial prefrontal cortex produce anxiolytic effects in the elevated plus-maze and shock-probe burying tests. Brain Res. 2003, 996(1):31-40.
40. Shekhar A., Truitt W., Rainnie D., Sajdyk T. Role of stress, corticotrophin releasing factor (CRF) and amygdala plasticity in chronic anxiety. Stress 2005, 8(4):209-219. (Rev.).
41. Silva A.J., Kogan J.H., Frankland P.W., Kida S. CREB and memory. Annu. Rev. Neurosci. 1998, 21:127-148.
42. Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Chen R., Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.F. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998, 20:1093-1102.
43. Steckler T., Holsboer F. Enhanced conditioned approach responses in transgenic mice with impaired glucocorticoid receptor function. Behav. Brain Res. 1999, 102:151-163.
44. Stenzel-Poore M.P., Heinrichs S.C., Rivest S., Koob G.F., Vale W.W. Overproduction of corticotropin-releasing factor in transgenic mice: a model of anxiogenic behavior. J. Neurosci. 1994, 14(5):2579-2584.
45. Stern C.M., Luoma J.I., Meitzen J., Mermelstein P.G. Corticotropin releasing factor-induced CREB activation in striatal neurons occurs via a novel Gβγ signaling pathway. PLoS One 2011, 6(3):e18114.
46. Tezval H., Jahn O., Todorovic C., Sasse A., Eckart K., Spiess J. Cortagine a specific agonist of corticotropin-releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse model. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(25):9468-9473.
47. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 1998, 19:162-166.
48. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 1993, 44:463-469.
49. Tully T. Toward a molecular biology of memory: the light's coming on!. Nat. Neurosci. 1998, 1(7):543-545.
50. Van Pett K., Viau V., Bittencourt J.C., Chan R.K., Li H.Y., Arias C., Prins G.S., Perrin M., Vale W., Sawchenko P.E. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol. 2000, 428:191-212.
51. Vita N., Laurent P., Lefort S., Chalon P., Lelias J.M., Kaghad M., Le Fur G., Caput D., Ferrara P. Primary structure and functional expression of mouse pituitary and human brain corticotropin releasing factor receptors. FEBS Lett. 1993, 335:1-5.
52. Xu Y., Krukoff T.L. Adrenomedullin in the rostral ventrolateral medulla inhibits baroreflex control of heart rate: a role for protein kinase A. Br. J. Pharmacol. 2006, 148(1):70-77.